Former Roche oncology head joins AAA board
This article was originally published in Scrip
Molecular nuclear medicines specialist, Advanced Accelerator Applications (AAA), has appointed Kapil Dhingra to its board of directors as an independent non-executive director. Prior to joining the AAA board, Dr Dhingra was head of oncology at Roche. He is currently head of KAPital Consulting, a healthcare consulting firm he founded in 2008, and is an advisor or member of several biotechnology and pharmaceutical companies' boards. Saint-Genis-Pouilly, France-based AAA's board is chaired by Claudio Costamagna and consists of nine directors.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.